Kala Bio (KALA) Total Liabilities (2016 - 2026)
Kala Bio (KALA) posted Total Liabilities of $1.6 million for Q1 2026, down 37.57% sequentially from $2.5 million in Q4 2025, and down 96.34% YoY from $42.5 million in Q1 2025.
Kala Bio (KALA) Total Liabilities (2016 - 2026) Analysis & Trends
Kala Bio has reported Total Liabilities for 11 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Total Liabilities fell 96.34% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 96.34% YoY) and the FY2025 annual result came in at $2.5 million, down 94.22% from the prior year.
- Total Liabilities eased to $1.6 million in Q1 2026 per KALA's latest filing, from $2.5 million in the prior quarter.
- Over five years, Total Liabilities peaked at $116.9 million in Q1 2022 and troughed at $1.6 million in Q1 2026.
- A 5-year average of $52.2 million and a median of $47.9 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities decreased 2.28% in 2024, then tumbled 96.34% in 2026.
- Over 5 years, Total Liabilities stood at $67.8 million in 2022, then fell by 28.6% to $48.4 million in 2023, then dropped by 10.93% to $43.2 million in 2024, then plunged by 94.22% to $2.5 million in 2025, then sank by 37.57% to $1.6 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $1.6 million, $2.5 million, and $33.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 2.49 Mn |
| Sep 30, 2025 | 33.69 Mn |
| Jun 30, 2025 | 39.26 Mn |
| Mar 31, 2025 | 42.54 Mn |
| Dec 31, 2024 | 43.15 Mn |
| Sep 30, 2024 | 47.22 Mn |
| Jun 30, 2024 | 47.89 Mn |
| Mar 31, 2024 | 46.37 Mn |
| Dec 31, 2023 | 48.45 Mn |
| Sep 30, 2023 | 49.90 Mn |
| Jun 30, 2023 | 49.01 Mn |
| Mar 31, 2023 | 48.77 Mn |
| Dec 31, 2022 | 67.85 Mn |
| Sep 30, 2022 | 86.67 Mn |
| Jun 30, 2022 | 116.53 Mn |
| Mar 31, 2022 | 116.86 Mn |
| Dec 31, 2021 | 122.62 Mn |
| Sep 30, 2021 | 132.35 Mn |
| Jun 30, 2021 | 131.19 Mn |